Trials / Unknown
UnknownNCT00426296
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Clinical Alliance for Research & Education - Infectious Diseases, LLC. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
Detailed description
Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at entry
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | atazanavir (Reyataz) | |
| DRUG | ritonavir (Norvir) |
Timeline
- Start date
- 2006-08-01
- First posted
- 2007-01-24
- Last updated
- 2007-11-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00426296. Inclusion in this directory is not an endorsement.